Single Ascending Dose Study of MEDI1341 in Healthy Volunteers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03272165 |
Recruitment Status :
Completed
First Posted : September 5, 2017
Last Update Posted : March 17, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is a study of single ascending intravenous doses of MEDI1341 or placebo in up to 48 healthy volunteers, aged 18 to 65 years.
The study will include up to 6 planned cohorts; each cohort will comprise 8 subjects.
Each subject will receive a single 60 minute intravenous infusion of MEDI1341 or placebo and will undergo scheduled assessments over a period of 13 weeks.
The main aim of the study is to assess the safety and tolerability of single doses of MEDI1341 in Healthy Volunteers.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Parkinson's Disease | Drug: MEDI1341 Drug: Placebo | Phase 1 |
This is a randomized, double-blind, placebo-controlled study of single ascending intravenous doses of MEDI1341 in male and nonfertile female healthy volunteers, aged 18 to 65 years.
The study will include up to 6 planned cohorts; each cohort will comprise 8 subjects. Within each cohort, 6 subjects will be randomized to receive MEDI1341 and 2 will be randomized to receive placebo. A Safety Review Committee will review data from each cohort before progression to the next higher dose cohort occurs.
On Day 1, each randomized subject will receive a single 60 minute intravenous infusion of MEDI1341 or placebo and will undergo scheduled safety, pharmacokinetic, pharmacodynamic, and immunogenicity assessments. Additional study assessments will occur on Days 2, 4, 8, 15, 22, 29, 43, 57, and 92.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Subjects are randomised to one of two groups within a cohort of 8 subjects (N=6 MEDI1341; N=2 placebo) |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers. |
Actual Study Start Date : | October 17, 2017 |
Actual Primary Completion Date : | March 31, 2021 |
Actual Study Completion Date : | March 31, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: MEDI1341 |
Drug: MEDI1341
Intravenous infusion over 60 minutes
Other Name: TAK-341 |
Placebo Comparator: Placebo |
Drug: Placebo
Intravenous infusion over 60 minutes |
- Adverse Events [ Time Frame: 13 weeks ]- Incidence, nature, severity and seriousness
- Vital Signs [ Time Frame: 13 weeks ]- Blood pressure and pulse rate
- Oral Body Temperature [ Time Frame: 13 weeks ]- in Celsius
- Body weight [ Time Frame: 13 weeks ]- in kilograms
- Height [ Time Frame: 13 weeks ]- in meters
- Body Mass Index (BMI) [ Time Frame: 13 weeks ]- Weight and height will be combined to report BMI in kg/m2
- Safety Laboratory tests [ Time Frame: 13 weeks ]- Clinical chemistry, hematology, coagulation, urinalysis
- Electrocardiograms [ Time Frame: 13 weeks ]- rhythm, heart rate, conduction, P-R interval, QRS complex, R-R interval, Q-T interval, and QTcF (Q-T interval corrected by Fridericia's formula)
- Ophthalmic assessments [ Time Frame: 13 weeks ]
- a standardized ophthalmic patient-reported outcome questionnaire
- visual acuity
- intraocular pressure
- corneal thickness
- slit-lamp examination
- fundoscopy
- optical coherence tomography
- visual field assessment
- Maximum concentration of Medi1341 [ Time Frame: 13 weeks ]- Cmax
- Time to maximum concentration of Medi1341 [ Time Frame: 13 weeks ]- tmax
- Area under the concentration - time curve of Medi1341 [ Time Frame: 13 weeks ]- AUC from zero to the last measurable concentration
- AUC of Medi1341 from zero to infinity [ Time Frame: 13 weeks ]- AUC0-∞
- Terminal half-life of Medi1341 [ Time Frame: 13 weeks ]- t1/2λz
- Clearance of Medi1341 [ Time Frame: 13 weeks ]- CL
- Volume of distribution of Medi1341 at steady state [ Time Frame: 13 weeks ]- Vss
- Mean residence time of Medi1341 [ Time Frame: 13 weeks ]- MRT
- Total alpha-synuclein concentrations [ Time Frame: 13 weeks ]- in plasma
- Free alpha-synuclein concentrations [ Time Frame: 29 days ]- in Cerebrospinal Fluid
- Anti-Drug Antibodies to MEDI1341 [ Time Frame: 13 weeks ]- in serum

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Subjects must be healthy, with no clinically significant abnormality identified on the medical or laboratory evaluation at screening
- Subjects must weigh ≥50 kg and must have a body mass index between 18 and 32 kg/m2, inclusive
- Subjects must have a 12-lead ECG recorded at screening that is normal for the appropriate age group and shows no abnormalities that will compromise safety in this study
- Subjects must have no clinically significant findings on the clinical neurological examinations at screening and at baseline or on the ophthalmic examination at screening.
Exclusion Criteria:
- Nicotine use within 6 months before screening
- Considered to be at a high risk of developing a stroke
- Significant medical history of dizziness, blackouts, fainting, or vaso-vagal attacks
- History of any significant ophthalmic disorder, including congenital, genetic or acquired conditions affecting the retina or choroid
- History of severe allergy or history of hypersensitivity to immunizations or immunoglobulins
- History of any significant psychiatric disorder
- History of alcohol abuse
- History of cancer within 5 years of screening
- History of drug abuse
- Any contraindication to Lumbar Puncture
- Any clinically significant abnormality in ECG rhythm, conduction or morphology
- Positive serologic findings at screening for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen, or hepatitis C virus antibodies
- Use of prescription or non-prescription drugs
- For female subjects, a positive serum or urine pregnancy test result at screening

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03272165
United States, Texas | |
Research Site | |
Dallas, Texas, United States, 75247 | |
United States, Wisconsin | |
Research Site | |
Madison, Wisconsin, United States, 53704 |
Principal Investigator: | Jeanelle Kam, MD, CPI | Covance Dallas CRU, USA | |
Principal Investigator: | John E Blanchard, MD | Covance Madison CRU, USA |
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT03272165 |
Other Study ID Numbers: |
D6340C00001 |
First Posted: | September 5, 2017 Key Record Dates |
Last Update Posted: | March 17, 2022 |
Last Verified: | February 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Qualified researchers can request access to anonymised individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure |
Time Frame: | AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure |
Access Criteria: | When a request has been approved, AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsor tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure |
URL: | https://astrazenecagroup-dt.pharmacm.com/DT/Home |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Healthy Volunteers Safety Tolerability |
Pharmacokinetics Pharmacodynamics Immunogenicity |
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases |